TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35221140

Group type: EXPERIMENTAL
Intervention: Single-fraction stereotactic ablative body radiotherapy (SABR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multi-fraction SABR regimens
Number of subjects: 0
Study: 33888528

Group type: EXPERIMENTAL
Intervention: High-dose erythropoietin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI and MRS biomarkers
Number of subjects: 0
Study: 32835443

Group type: EXPERIMENTAL
Intervention: Unilateral sacral neuromodulation testing
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bilateral sacral neuromodulation testing
Number of subjects: 55
Study: 34042314

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 150 mg once daily
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Fenebrutinib 200 mg twice daily
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Fenebrutinib (both dosages)
Number of subjects: 260
Study: 32479750

Group type: EXPERIMENTAL
Intervention: Acetazolamide 62.5 mg twice daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Acetazolamide 125 mg twice daily
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 35304395

Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 0
Study: 33439695

Group type: EXPERIMENTAL
Intervention: 3-month treatment (CAPOX or FOLFOX)
Number of subjects: 3273

Group type: COMPARATOR
Intervention: 6-month treatment (CAPOX or FOLFOX)
Number of subjects: 3273

Group type: EXPERIMENTAL
Intervention: CAPOX (3-month or 6-month)
Number of subjects: 3273

Group type: EXPERIMENTAL
Intervention: FOLFOX (3-month or 6-month)
Number of subjects: 3273
Study: 34996794

Group type: COMPARATOR
Intervention: Information condition (usual care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivation condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Action condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 0
Study: 32654257

Group type: EXPERIMENTAL
Intervention: Automated phone intervention (self-scheduling text or phone message)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard-of-care written instructions (control)
Number of subjects: 278
Study: 36445663

Group type: EXPERIMENTAL
Intervention: Ganglion plexus (GP) ablation
Number of subjects: 204

Group type: COMPARATOR
Intervention: No GP ablation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 204
Study: 32770531

Group type: EXPERIMENTAL
Intervention: Ticagrelor loading dose (180 mg)
Number of subjects: 30
Study: 35850739

Group type: EXPERIMENTAL
Intervention: Diagnostic to measure reactive dynamic balance
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Intensive testing in the gait laboratory
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Focus group interviews
Number of subjects: 450
Study: 32037209

Group type: EXPERIMENTAL
Intervention: Cold sterilization (glutaraldehyde)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hot sterilization (autoclave)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ortho Organizers brand
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: American Orthodontics brand
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: SIA brand
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gestenco brand
Number of subjects: 120
Study: 36441270

Group type: EXPERIMENTAL
Intervention: DFDBA plus CGF membrane
Number of subjects: 30

Group type: COMPARATOR
Intervention: DFDBA alone (control group)
Number of subjects: 30
Study: 33632264

Group type: EXPERIMENTAL
Intervention: HETROM-2.5 (2.5 mg hetrombopag once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HETROM-5 (5 mg hetrombopag once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34293141

Group type: EXPERIMENTAL
Intervention: Positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S)
Number of subjects: 14628
Study: 33963089

Group type: EXPERIMENTAL
Intervention: Cow's milk exclusion diet for the first 4 months of life
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Soya milk preparation offered to intervention group
Number of subjects: 487

Group type: COMPARATOR
Intervention: Normal diet (control)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Earlier exposure to soya milk
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Wheeze
Number of subjects: 487
Study: 33261155

Group type: EXPERIMENTAL
Intervention: Egg group (2 eggs for breakfast 5 days per week)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cereal group (breakfast cereal)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Egg group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cereal group
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Egg group (post-hoc analysis of obese participants)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cereal group (post-hoc analysis of obese participants)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 34018237

Group type: EXPERIMENTAL
Intervention: e-Oral health text messages
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard dental leaflets
Number of subjects: 150
Study: 33762086

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Weight Loss (WL)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 165
Study: 32754748

Group type: EXPERIMENTAL
Intervention: High-dose SRL (lanreotide 120 mg/octreotide long-acting release [LAR] 30 mg) plus weekly pegvisomant (40-160 mg/week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose SRL (lanreotide 60 mg/octreotide LAR 10 mg) plus weekly pegvisomant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose SRL plus daily pegvisomant (15-60 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose SRL (lanreotide 120 mg/octreotide LAR 30 mg) plus weekly pegvisomant (40-160 mg/week)
Number of subjects: 60
Study: 35266670

Group type: EXPERIMENTAL
Intervention: Immediate loading and under-drilling
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Immediate loading and complete drilling
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Early loading and under-drilling
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Early loading and complete drilling
Number of subjects: 44
Study: 35381609

Group type: EXPERIMENTAL
Intervention: Pregestational DM
Number of subjects: 5436

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 5436

Group type: COMPARATOR
Intervention: Control group (without DM)
Number of subjects: 5436
Study: 33417306

Group type: EXPERIMENTAL
Intervention: Deep learning model using molecular descriptors as drug structure information
Number of subjects: 380
Study: 36130765

Group type: EXPERIMENTAL
Intervention: Dual mobility THA
Number of subjects: 1536

Group type: COMPARATOR
Intervention: Conventional THA
Number of subjects: 1536
Study: 34933737

Group type: EXPERIMENTAL
Intervention: AgNPs
Number of subjects: 0
Study: 32118256

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 5929

Group type: COMPARATOR
Intervention: No reperfusion therapy (Control)
Number of subjects: 5929
Study: 35469330

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32220091

Group type: EXPERIMENTAL
Intervention: PRISMS form (intervention group)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 202
Study: 33640444

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 mcg/kg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 mcg/kg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 120
Study: 34110581

Group type: EXPERIMENTAL
Intervention: Multicomponent health behavioral intervention delivered through teachers
Number of subjects: 0
Study: 32681463

Group type: EXPERIMENTAL
Intervention: Oral contraceptives containing Cyproterone Acetate (CPA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral contraceptives containing Levonorgestrel (LNG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral contraceptives containing Desogestrel (DSG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral contraceptives containing Drospirenone (DRSP)
Number of subjects: 120
Study: 32357900

Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 100
Study: 34039690

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM) with alarms set at 2.61-10 mmol/L (47-180 mg/dL)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group with alarms set at 3.44-7.78 mmol/L (62-140 mg/dL)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Strict protocol using CGM
Number of subjects: 48
Study: 33516483

Group type: COMPARATOR
Intervention: Dexamethasone (DEX) 1.5 mg/kg of diet
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 1.5 mg/kg of diet and omega-3 fatty acids supplementation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.48% omega-3 fatty acids
Number of subjects: 96
Study: 35488238

Group type: EXPERIMENTAL
Intervention: 6-month diet intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-month exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-month combined diet and exercise intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous interventions
Number of subjects: 0
Study: 34508740

Group type: EXPERIMENTAL
Intervention: Iron infusion (iron (III)-hydroxide sucrose; 200mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 46
Study: 34734227

Group type: EXPERIMENTAL
Intervention: STRSI-guided LV lead positioning
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional implantation (Control)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 172
Study: 33359908

Group type: EXPERIMENTAL
Intervention: Lateral quadratus lumborum block (QLB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 0
Study: 32105093

Group type: EXPERIMENTAL
Intervention: Text message reminders to avoid safety behaviors (SBs)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Present-focused text message condition
Number of subjects: 94
Study: 35078150

Group type: EXPERIMENTAL
Intervention: Self-myofascial release program (FOAM) 3 times per week for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study: 33633408

Group type: EXPERIMENTAL
Intervention: OAS1 levels (increased)
Number of subjects: 14134
Study: 32723088

Group type: EXPERIMENTAL
Intervention: Feldenkrais method
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (core stability exercises)
Number of subjects: 60
Study: 33278048

Group type: EXPERIMENTAL
Intervention: Zirconia implant under experimental mucositis conditions (Zr-m)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Titanium implant under experimental mucositis conditions (Ti-m)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Zirconia implant under healthy conditions (Zr-h)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Titanium implant under healthy conditions (Ti-h)
Number of subjects: 42
Study: 32338104

Group type: EXPERIMENTAL
Intervention: Cephalomedullary nailing
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Threshold value of fracture height
Number of subjects: 50
Study: 34903479

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Cardiovascular mortality
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Heart failure hospitalizations
Number of subjects: 320
Study: 32503949

Group type: EXPERIMENTAL
Intervention: TPIV200 and durvalumab
Number of subjects: 27
Study: 35342642

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise programme using rubber bands and stretching
Number of subjects: 579

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 579
Study: 32683477

Group type: EXPERIMENTAL
Intervention: Dynamic Q-angle gait pattern during normal walking in patients with chronic patellofemoral instability
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Femoral antetorsion (femAT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tibial tubercle-trochlear groove (TT-TG) distance
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dynamic valgus in a single-leg squat
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Static measured Q-angle
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trendelenburg's sign
Number of subjects: 35
Study: 35916813

Group type: EXPERIMENTAL
Intervention: 5.2 g PHGG daily for 12 weeks
Number of subjects: 96
Study: 32998756

Group type: EXPERIMENTAL
Intervention: Cemented total hip replacement (CTR)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Uncemented total hip replacement (UTR)
Number of subjects: 268
Study: 36461909

Group type: EXPERIMENTAL
Intervention: Pedometer-based walking program (>7500 steps/day for 5 days/week) plus resistance exercise (elastic band, twice/week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Interaction effect between intervention and control groups
Number of subjects: 90
Study: 32736036

Group type: EXPERIMENTAL
Intervention: Resilience at 6 weeks after surgery
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Self-efficacy at 6 weeks after surgery
Number of subjects: 248
Study: 32053158

Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medicare Beneficiaries
Number of subjects: 0
Study: 34142251

Group type: EXPERIMENTAL
Intervention: Early rehabilitation (knee extension exercise started within 4 hours after surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control rehabilitation (knee extension exercise started 2 days after surgery)
Number of subjects: 80
Study: 35122820

Group type: EXPERIMENTAL
Intervention: 100 BC: 00 FYM (sole biochar)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 BC: 25 FYM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 BC: 50 FYM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 BC: 75 FYM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 00 BC: 100 FYM
Number of subjects: 0

Group type: COMPARATOR
Intervention: 00 BC: 00 FYM
Number of subjects: 0
Study: 33754800

Group type: EXPERIMENTAL
Intervention: Intra-articular allogenic lyophilized growth factors (L-GFs), two doses at baseline and after 2 months
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 31
Study: 36250945

Group type: EXPERIMENTAL
Intervention: Substantial limitations in physical function at baseline
Number of subjects: 2950
Study: 33278935

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200 mg every 3 weeks plus nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 847
Study: 33660114

Group type: EXPERIMENTAL
Intervention: Black seed raisin (90 g per day)
Number of subjects: 38
Study: 33942294

Group type: EXPERIMENTAL
Intervention: Reporting of randomized controlled trial abstracts according to CONSORT guidelines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 34446500

Group type: EXPERIMENTAL
Intervention: Helmet non-invasive ventilation (NIV) with usual care
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320
Study: 35686512

Group type: EXPERIMENTAL
Intervention: Educational digital video disc plus routine education
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine education only
Number of subjects: 120
Study: 33439284

Group type: EXPERIMENTAL
Intervention: Communication technology enhanced transition coordinator intervention
Number of subjects: 203

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 203
Study: 32352493

Group type: EXPERIMENTAL
Intervention: AAV8.CNGA3 gene therapy (1.0 × 10^10, 5.0 × 10^10, or 1.0 × 10^11 total vector genomes)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AAV8.CNGA3 gene therapy
Number of subjects: 9
Study: 36280159

Group type: EXPERIMENTAL
Intervention: Optimized TNQ
Number of subjects: 127

Group type: COMPARATOR
Intervention: Without TNQ
Number of subjects: 127
Study: 33257457

Group type: EXPERIMENTAL
Intervention: Polypharmacy (5-9 medications)
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: Hyperpolypharmacy (10-14 medications)
Number of subjects: 1761

Group type: EXPERIMENTAL
Intervention: Super hyperpolypharmacy (≥15 medications)
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Control group (<5 medications)
Number of subjects: 1761
Study: 35465777

Group type: EXPERIMENTAL
Intervention: MINDS Optimal Health Program (OHP) - nine sessions over twelve months
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study: 33397442

Group type: EXPERIMENTAL
Intervention: Low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard immunosuppression protocol after alemtuzumab induction therapy
Number of subjects: 110
Study: 35380498

Group type: EXPERIMENTAL
Intervention: Tobacco smokers
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ENDS users
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 44
Study: 33952416

Group type: EXPERIMENTAL
Intervention: Social Engage (S‐ENG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 62
Study: 35576292

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 930

Group type: COMPARATOR
Intervention: Probiotics (lactobacillus rhamnosus)
Number of subjects: 930
Study: 33243723

Group type: EXPERIMENTAL
Intervention: Five-session body image intervention delivered by teachers
Number of subjects: 1495

Group type: COMPARATOR
Intervention: Lessons-as-usual control
Number of subjects: 1495
Study: 91032514

Group type: EXPERIMENTAL
Intervention: HBV vaccine 5 microgram
Number of subjects: 0

Group type: COMPARATOR
Intervention: HBV vaccine 2 microgram
Number of subjects: 0
Study: 35051671

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 204
Study: 34237425

Group type: EXPERIMENTAL
Intervention: Glycerol 25% replacement of corn
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Glycerol 50% replacement of corn
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Glycerol 75% replacement of corn
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Glycerol 100% replacement of corn
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (0% glycerol replacement)
Number of subjects: 240
Study: 35810756

Group type: EXPERIMENTAL
Intervention: Thrombectomy alone
Number of subjects: 408

Group type: COMPARATOR
Intervention: Intravenous alteplase plus thrombectomy
Number of subjects: 408
Study: 34708555

Group type: EXPERIMENTAL
Intervention: Standardized diuretic protocol (Phase 2) based on HFA algorithm, starting with intravenous administration of two times the oral home dose.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard of care (Phase 1)
Number of subjects: 500
Study: 32205206

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Xenogenic Collagen Matrix (XCM)
Number of subjects: 75
Study: 35148750

Group type: EXPERIMENTAL
Intervention: Heallagen® (7 g L-arginine, 7 g L-glutamine, 1.5 g HMB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 60
Study: 35273045

Group type: EXPERIMENTAL
Intervention: Decision thresholds (DTs) derived from the GRADE EtD frameworks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Judgments made by guideline panels
Number of subjects: 0
Study: 34620663

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: HPV testing starting at age 30
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: Extended screening interval of 4-5 years
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: HPV positive screen test result
Number of subjects: 5532

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 5532
Study: 35718307

Group type: EXPERIMENTAL
Intervention: Supervised exercise delivered via Telehealth (Coviu) for eight weeks by an Accredited Exercise Physiologist in a group setting.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (receiving physical activity guidelines).
Number of subjects: 160
Study: 35772447

Group type: EXPERIMENTAL
Intervention: VPM1002
Number of subjects: 416

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 416
Study: 32809014

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 402
Study: 32822653

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 35511290

Group type: EXPERIMENTAL
Intervention: xenogenic bone + autogenous bone (ratio 70:30)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: xenogenic bone + L‐PRF
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: xenogenic bone
Number of subjects: 36
Study: 32533742

Group type: EXPERIMENTAL
Intervention: Psychoeducation programme (six face-to-face interventions)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Care as usual (six routine prenatal examinations)
Number of subjects: 238
Study: 36301306

Group type: EXPERIMENTAL
Intervention: PBM combined with stretching
Number of subjects: 54

Group type: COMPARATOR
Intervention: PBM
Number of subjects: 54

Group type: COMPARATOR
Intervention: Low-intensity stretching
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 54